ab16790 ACVR2A Antibody

Western blot analysis of extracts from Colo205, using ACVR2A Antibody. The lane on the left was treated with blocking peptide. Observed bands: 80 kDa.

ab16790 at 1/100 staining Human pancreatic cancer and adjacent nomal tissues by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the primary antibody at 4°C overnight. An HRP conjugated anti-Rabbit antibody was used as the secondary antibody.

ab16790 staining Hela cells by IF/ICC. The samples were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. Samples were then incubated with primary Ab(ab16790 1:200) and mouse anti-beta tubulin Ab(T0023 1:200) for 1 hour at 37°C. An AlexaFluor594 conjugated goat anti-rabbit IgG(H+L) Ab(Red) and an AlexaFluor488 conjugated goat anti-mouse IgG(H+L) Ab(Green) were used as the secondary antibody. The nuclear counter stain is DAPI(blue).

Figure 9 Identification of the miR-192 target gene. (A) Bubble chart indicating the KEGG pathways associated with miR-192 targets. (B) GO enrichment analysis of miR-192 targets. (C) The predicted binding region between miR-192 and Acvr2a mRNA was predicted using bioinformatics analysis. (D) Luciferase activity assay. (E) The mRNA expression of Acvr2a was assessed in GCs transfected with miR-192 mimics via RT-PCR. (F) At 48 h post-transfection, ACVR2A protein level in cultural PGCs was determined via Western blotting. GAPDH expression levels were used to normalize protein levels. Data are presented as means ± SE. (n = 3). ** p < 0.01.